Ardelyx Forecasts $410–430M IBSRELA, $110–120M XPHOZAH 2026 Sales
ARDX•Ardelyx forecasts combined 2026 revenue from IBSRELA and XPHOZAH to exceed $500 million, with IBSRELA at $410–430 million and XPHOZAH at $110–120 million. The company reiterated targets of $1 billion IBSRELA sales by 2029 and $750 million peak for XPHOZAH, while guiding 2026 operating expenses up to $520 million.
1. Combined Product Revenue Forecast
Ardelyx forecasts combined 2026 revenue from IBSRELA and XPHOZAH to exceed $500 million, with IBSRELA contributing $410–430 million and XPHOZAH $110–120 million to the total.
2. 2026 Priorities and Expense Guidance
The company outlined four priorities for 2026, including growing IBSRELA demand and maintaining XPHOZAH momentum, and guided operating expenses up to $520 million driven by a sales force expansion from 124 to 144 representatives and enhanced patient-activation programs.
3. Pipeline Trial Progress
Ardelyx’s late-stage trial of IBSRELA in chronic idiopathic constipation remains on schedule for full enrollment by year-end, with top-line data expected in mid-2027, representing a key pipeline catalyst.
4. Long-Term Targets and Profitability Outlook
Management reiterated a $1 billion sales target for IBSRELA by 2029 and a $750 million peak for XPHOZAH, while emphasizing that profitability is expected in the near term once top-line results provide further clarity.
